	US 12,280,120 B2
	Tumor-specific cleavable linkers
Raphael Rozenfeld, Swampscott, MA (US); Ugur Eskiocak, Somerville, MA (US); Huawei Qiu, Westborough, MA (US); Parker Johnson, Allston, MA (US); Kurt Allen Jenkins, Weymouth, MA (US); Magali Pederzoli-Ribeil, Cambridge, MA (US); Dheeraj Singh Tomar, Dorchester, MA (US); and Rebekah Kay O'Donnell, Brookline, MA (US)
Assigned to Xilio Development, Inc., Waltham, MA (US)
Filed by Xilio Development, Inc., Waltham, MA (US)
Filed on Nov. 24, 2021, as Appl. No. 17/535,451.
Claims priority of provisional application 63/253,090, filed on Oct. 6, 2021.
Claims priority of provisional application 63/118,585, filed on Nov. 25, 2020.
Prior Publication US 2023/0072822 A1, Mar. 9, 2023
Int. Cl. A61K 47/65 (2017.01); A61K 38/20 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01)

CPC A61K 47/65 (2017.08) [A61K 38/2013 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61K 47/64 (2017.08); A61P 35/00 (2018.01)]

11 Claims

1. A masked interleukin 12 (IL-12) cytokine comprising:

a first polypeptide chain comprising a first Fc domain, and a masking moiety comprising the amino acid sequence of SEQ ID NO: 220;

a second polypeptide chain comprising a second Fc domain, a first linker comprising a proteolytically cleavable peptide of SEQ ID NO: 249, and an IL-12 cytokine comprising an IL-12p40 polypeptide linked to an IL-12p35 polypeptide; and

wherein the IL-12p40 polypeptide comprises the amino acid sequence of SEQ ID NO: 208 and the IL-12p35 polypeptide comprises the amino acid sequence of SEQ ID NO: 209.